Case Study
Sponsored by an educational grant from QuidelOrtho
That’s why I get out
of bed every morning
and that’s why I’m
so passionate about
what we’re doing.”
Duane Jones, BS Pharm, PD
Evaluate resources for implementation in your state
• NCPA • CPESN
Establish clinical protocols for testing, treatment and physician referral
Contact the Department of Health in your state
• CLIA waiver • Reporting requirements
Credential pharmacists AND pharmacy with payers
• Different payers have different requirements
Implement workflow to provide pharmacists flexibility to see patients
• Train pharmacy technicians on all non-clinical tasks and medical billing
• Utilize medication synchronization
Steps for test-and-treat implementation
The final result
Duane has, over many years, collected test-and-treat data from the Harps working pharmacies.
He has partnered with Elevance Health Inc., an American for-profit health insurance provider, and
CPESN, who together have collaborated to publish studies reporting that pharmacy intervention in
medication therapy saved 35% in hospital visits and 15% in emergency visits.8 He is presently working
with other organizations to provide more health economic data. He and his team feel certain that the
data will show more cost savings. He explains it this way, “The [insurance] plans will get on board with
compensating for these [pharmacy test-and-treat] services because they see how much money they’re
going to save. For us, our win is a healthy patient. That’s why I get out of bed every morning and that’s
why I’m so passionate about what we’re doing.”
Will patients adopt?
The best way to encourage patients to use pharmacy test-and-treat is to market directly to the
patient. Jennifer agrees that this is a new concept for many people. Marketing is a process that
they are still learning and evolving. She explains, “Since starting our test-and-treat program, we’ve
created bag stuffers and added eye-catching signage inside each pharmacy. We actively promote
our services on Facebook and Instagram where our audience continues to grow. But honestly, our
most effective marketing is word of mouth. Once patients experience how convenient and simple
the process is, they tend to tell other people.”
Hear the interview at
On Medical Grounds podcast,
your source for engaging,
relevant, evidence-based
medical information.
8. Healthcare Innovation Caucus -
Role of CP in VBPM 2018. www.nacds.org.
Accessed 27 May 2025.
• RSV
• Flu + SARS Antigen*
• SARS Antigen*
Be prepared for all your patient
testing needs with advanced
diagnostic solutions from
QuidelOrtho. Including Sofia 2
SARS Antigen+ FIA, the first
FDA-cleared, 10-minute rapid
antigen test for COVID-19.†
Test smart,
breathe easy
The Sofia™ 2 Analyzer makes elevating
customer service to patient care with
test-to-treat solutions easy
• SARS Antigen+†
• Influenza A+B
• Strep A+
*Available under Emergency Use Authorization
†Sofia 2 SARS Antigen+ FIA received De Novo FDA clearance on March 8, 2023 and CLIA waiver
from the FDA on September 20, 2023
New QuidelOrtho branding may not be available in all markets, subject to country specific
regulatory approval. Please confirm with your local commercial team.
© 2025 QuidelOrtho Corporation. All rights reserved. PR-108737-NA-EN-US-v1
*In the USA, this product has not been FDA cleared or approved, but has been authorized by
FDA under an Emergency Use Authorization. This product has been authorized only for the
detection of proteins from SARS-CoV-2, infl uenza A, and infl uenza B, not for any other viruses
or pathogens. The emergency use of this product is only authorized for the duration of the
declaration that circumstances exist justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal
Food, Drug, and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated
or authorization is revoked sooner.
For more
information
scan the
QR code